Cryoport Inc's Corporate Customers have recorded an increase in their cost of revenue by 10.41 % in the 2 quarter 2026 year on year, sequentially costs of revenue grew by 4.23 %. During the corresponding time, Cryoport Inc recorded a revenue increase by 7.74 % year on year, sequentially revenue grew by 2.45 %. While revenue at the Cryoport Inc 's corporate clients recorded rose by 5.31 % year on year, sequentially revenue grew by 3.97 %.
Cryoport Inc's Customers have recorded an increase in their cost of revenue by 10.41 % in the 2 quarter 2026 year on year, sequentially costs of revenue grew by 4.23 %, for the same period Cryoport Inc recorded revenue increase by 7.74 % year on year, sequentially revenue grew by 2.45 %.
Cryoport Inc's Comment on Sales, Marketing and Customers
The company provides storage, handling, and delivery services for high-value, temperature-sensitive biological materials, with a focus on the cell and gene therapy (CGT) market. As of December 31, 2025, it supported 760 clinical trials and 20 commercially approved cell and gene therapies. Its integrated temperature-controlled supply chain solutions cover cell and gene therapy programs from preclinical research through clinical trials to global commercialization. The company operates through three units: Cryoport Systems, CryoGene, and MVE Biological Solutions, offering logistics, biostorage, cryopreservation, and cryogenic systems manufacturing. It divested its specialty courier business, CRYOPDP, to DHL Supply Chain International Holding B.V. for $133.0 million, including repayment of intercompany loans, and entered a master partnership agreement with DHL to support business development in the EMEA and APAC regions. The CRYOPDP business is classified as discontinued operations; all other information pertains to continuing operations.
Cryoport Inc’s Comment on Sales, Marketing and Customers
The company provides storage, handling, and delivery services for high-value, temperature-sensitive biological materials, with a focus on the cell and gene therapy (CGT) market. As of December 31, 2025, it supported 760 clinical trials and 20 commercially approved cell and gene therapies. Its integrated temperature-controlled supply chain solutions cover cell and gene therapy programs from preclinical research through clinical trials to global commercialization. The company operates through three units: Cryoport Systems, CryoGene, and MVE Biological Solutions, offering logistics, biostorage, cryopreservation, and cryogenic systems manufacturing. It divested its specialty courier business, CRYOPDP, to DHL Supply Chain International Holding B.V. for $133.0 million, including repayment of intercompany loans, and entered a master partnership agreement with DHL to support business development in the EMEA and APAC regions. The CRYOPDP business is classified as discontinued operations; all other information pertains to continuing operations.
Sources:
Cryoport inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Cryoport inc’s corporate clients.
For your research, we’ve provided 9 tables on Cryoport inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
112.04 %
4.07 %